EU COVID-19 Vaccine and Therapeutics Insights, Trends, and Growth Opportunities

EU COVID-19 Vaccine and Therapeutics Insights, Trends, and Growth Opportunities

Future Growth Potential Driven by Capabilities and Expertise in Vaccine Manufacturing

RELEASE DATE
26-Nov-2021
REGION
Europe
Research Code: PC55-01-00-00-00
SKU: HC03475-EU-MT_26006
$2,450.00
In stock
SKU
HC03475-EU-MT_26006
$2,450.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

With this research service, Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, the study identifies actionable growth opportunities for industry participants. Like the United States, the European Union received criticism for vaccine nationalism, but it is taking steps to encourage global vaccine access. It has launched the Team Europe initiative for improving manufacturing and access to vaccines, medicines, and health technologies in Africa.

Initiatives such as the EU Digital Vaccination Passport and UK NHS COVID Pass app will help Europe in safe reopening and overcoming COVID-19 variants of concern to a certain extent. Although vaccinations are progressing at a fast pace, factors that will determine campaigns’ future course include political and religious situations, vaccine availability and access, and vaccine hesitancy specifically in younger population groups. The low vaccination rate in Central and Eastern Europe (CEE) is fueling another COVID-19 surge (especially because of the Delta variant) and causing a healthcare crisis in Bulgaria, Romania and Latvia.

Topics covered include:
•     Analyses of COVID-19 vaccines and therapeutics
•     Strategies of vaccine manufacturers to scale up their global manufacturing network
•     COVID-19 vaccination rollouts
•     The role of digital technology in the COVID-19 battle
•     The Growth Opportunity Universe

Author: Surbhi Gupta

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives for the EU COVID-19 Vaccine and Therapeutics Market

Growth Opportunities Fuel the Growth Pipeline Engine™

Highlights

Regional Impact of COVID-19 Vaccinations

Scope of Analysis

Growth Drivers for Recovery from the COVID-19 Pandemic

Growth Restraints for Recovery from the COVID-19 Pandemic

COVID-19 Vaccine Pipeline Analysis

Overview of Key Authorized COVID-19 Vaccines Globally

Selected Vaccine Candidates in Phase III

Key Small Molecules in Late Stage of Development (Antivirals and Immunomodulators)

Key mAbs in Late Stage of Development

EU COVID-19 Therapeutics Snapshot

Pfizer/BioNTech Vaccines

Moderna

J&J

Oxford/AZ

Novavax

Capacity Secured

Distribution of COVID-19 Vaccine Doses by Manufacturer

Percentage of Adults Fully Vaccinated Against COVID-19

COVID-19 Vaccination Doses Administered in Selected Countries

Germany—Approaching the 70% First-dose Milestone

France—More than 70% of the Population Fully Vaccinated

Italy—Reached the 70% First-dose Milestone

UK—First European Country to Reach the 70% First-dose Milestone

Behind the Successful UK Rollout

DHL Express Hub and Gateway Model

Digital Technology Platforms Enabling Data Management, Vaccination, and Rebounding from COVID-19

 EU COVID-19 Certificate/Health Pass

IBM Digital Health Pass

Growth Opportunity 1—Additional and Booster Doses for Waning Immunity and Emerging Virus Variants

Growth Opportunity 1—Additional and (continued)

Growth Opportunity 2—Strengthening Domestic Manufacturing for Leading Global Supply of COVID-19 Vaccine

Growth Opportunity 2—Strengthening Domestic Manufacturing for Leading Global Supply of COVID-19 Vaccine (continued)

Growth Opportunity 3—Global Standard Solution for Recognising and Verifying Individual Countries’ COVID-19 Health Pass

Growth Opportunity 3—Global Standard Solution for Recognising and Verifying Individual Countries’ COVID-19 Health Pass (continued)

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

Related Research
With this research service, Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the European Union and UK COVID-19 vaccine and therapeutics market. The report analyzes COVID-19 vaccines and therapeutics in development and delves into supply chain considerations and requirements to manage distribution. Importantly, the study identifies actionable growth opportunities for industry participants. Like the United States, the European Union received criticism for vaccine nationalism, but it is taking steps to encourage global vaccine access. It has launched the Team Europe initiative for improving manufacturing and access to vaccines, medicines, and health technologies in Africa. Initiatives such as the EU Digital Vaccination Passport and UK NHS COVID Pass app will help Europe in safe reopening and overcoming COVID-19 variants of concern to a certain extent. Although vaccinations are progressing at a fast pace, factors that will determine campaigns’ future course include political and religious situations, vaccine availability and access, and vaccine hesitancy specifically in younger population groups. The low vaccination rate in Central and Eastern Europe (CEE) is fueling another COVID-19 surge (especially because of the Delta variant) and causing a healthcare crisis in Bulgaria, Romania and Latvia. Topics covered include: • Analyses of COVID-19 vaccines and therapeutics • Strategies of vaccine manufacturers to scale up their global manufacturing network • COVID-19 vaccination rollouts • The role of digital technology in the COVID-19 battle • The Growth Opportunity Universe Author: Surbhi Gupta
More Information
No Index No
Podcast No
Author Surbhi Gupta
Industries Healthcare
WIP Number PC55-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,9611-B1